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Background: Gonadotropin-releasing hormone (GnRH) and its receptor (GnRHR) are both expressed by a number
of malignant tumors, including those of the breast. In the latter, both behave as potent inhibitors of invasion.
Nevertheless, the signaling pathways whereby the activated GnRH/GnRHR system exerts this effect have not been
clearly established. In this study, we provide experimental evidence that describes components of the mechanism(s)
whereby GnRH inhibits breast cancer cell invasion.
Methods: Actin polymerization and substrate adhesion was measured in the highly invasive cell line, MDA-MB-231
transiently expressing the wild-type or mutant DesK191 GnRHR by fluorometry, flow cytometric analysis, and
confocal microscopy, in the absence or presence of GnRH agonist. The effect of RhoA-GTP on stress fiber formation
and focal adhesion assembly was measured in MDA-MB-231 cells co-expressing the GnRHRs and the GAP domain
of human p190Rho GAP-A or the dominant negative mutant GAP-Y1284D. Cell invasion was determined by the
transwell migration assay.
Results: Agonist-stimulated activation of the wild-type GnRHR and the highly plasma membrane expressed mutant
GnRHR-DesK191 transiently transfected to MDA-MB-231 cells, favored F-actin polymerization and substrate
adhesion. Confocal imaging allowed detection of an association between F-actin levels and the increase in stress
fibers promoted by exposure to GnRH. Pull-down assays showed that the effects observed on actin cytoskeleton
resulted from GnRH-stimulated activation of RhoA GTPase. Activation of this small G protein favored the marked
increase in both cell adhesion to Collagen-I and number of focal adhesion complexes leading to inhibition of the
invasion capacity of MDA-MB-231 cells as disclosed by assays in Transwell Chambers.
Conclusions: We here show that GnRH inhibits invasion of highly invasive breast cancer-derived MDA-MB-231 cells.
This effect is mediated through an increase in substrate adhesion promoted by activation of RhoA GTPase and
formation of stress fibers and focal adhesions. These observations offer new insights into the molecular
mechanisms whereby activation of overexpressed GnRHRs affects cell invasion potential of this malignant cell line,
and provide opportunities for designing mechanism-based adjuvant therapies for breast cancer.
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Breast cancer is the main cause of death from cancer in
women. In terms of number of new cases, this malig-
nancy represents the third most frequent cancer and the
ratio of mortality to incidence is about 61% [1]. Chemo-
therapy is central in the treatment of breast cancer, how-
ever it is well known that antineoplastic agents may
cause serious adverse and toxic effects [2]. Although ma-
lignant breast tumors can be responsive to initial chemo-
therapy, the development of intrinsic or acquired
multidrug resistance limits malignant tumor cells treat-
ments and restricts subsequent responses to therapy
[2,3]. Development and growth of metastases at distant
sites are the principal cause of death among breast can-
cer patients, being responsible for approximately 90% of
deaths from this malignant disease [4,5]; further, in
metastatic tumors, the response rates to first line che-
motherapies, either by single or combined drugs, range
from 30-70% with remission periods following treatment
of only 7–10 months [3]. Therefore, the development of
alternative therapies to prevent or ameliorate the fatal
course of this disease is essential.
The metastatic process comprises an ordered series of
events in which the acquisition of a motile and invasive
phenotype to penetrate the extracellular matrix (ECM) is
one of the earliest steps and a key determinant of the in-
vasive potential of tumor cells [6]. During cell migration,
the so-called focal adhesion complex (FA) serves as a
point of control for cell migratory potential by regulating
the continuous formation and turnover of cell substra-
tum contacts as well as actin polymerization. The regu-
lation of actin cytoskeleton during cell locomotion and
adhesion is performed by small G proteins from the Rho
family, which comprises several members, including
RhoA, Rac1, and Cdc42 [7]. RhoA is responsible for the
development of stress fibers and focal adhesion assembly
[8]. Although the specific mechanisms that control the
assembly of the FA and cell substrate-adhesion factors
are not well understood, the importance of RhoA in this
process has been demonstrated by in vitro studies. For
example, in cultured cells low levels of activated-RhoA
have been found to be associated with a high migration
phenotype [9,10] whereas, in contrast, high RhoA activ-
ity has been linked to poor migration ability by high sub-
strate adhesion [11-13]. Thus, it appears that RhoA is a
key regulator of cell adhesion and motility in cancer
cells.
Gonadotropin-releasing hormone (GnRH), a decapep-
tide synthesized in the hypothalamus, and its receptor,
the gonadotropin-releasing hormone receptor (GnRHR),
a G protein-coupled receptor located in the membrane
of the gonadotrophs of the anterior pituitary [14], are
key regulators of reproductive function. However, it has
been found that the GnRHR is not exclusively expressedin the anterior pituitary gland but also in other repro-
ductive tissues such as the breast, endometrium, ovary,
and prostate as well as in tumors derived from these tis-
sues, where it probably regulates cell proliferation and
tumor invasiveness [15-18]. In fact, GnRH and some of
its agonists have shown to be effective in controlling
tumor growth and invasiveness in in vitro and in vivo
systems [19-21]. Further, several studies have shown that
the ability of the GnRH/GnRHR system to reduce cell
tumor invasion and metastatic potential are associated
with up regulation of actin cytoskeleton remodeling,
mainly through the activation of Rac1 [22,23] as well as
by influencing the activity of cell-cell adhesion molecules
and/or the regulation of cell substrate attachment-
associated proteins [24,25]. These observations have
provided new insights into opportunities for adjuvant
therapies based on disruption of these processes.
Approximately 50-60% of breast cancer tumors as well
as several breast cancer-derived cell lines express specific
binding sites for GnRH [26,27]. The role of GnRH and
GnRH agonists (GnRHa) to inhibit growth of breast can-
cer cells has been demonstrated in both in vitro [18] and
in vivo models [15,16,19]. Likewise, the ability of GnRH
and GnRHa to reduce the migratory potential of these
cells has also been established [20,21]. Nevertheless, at
this point much less is known about the molecular
mechanisms subserving the effects of the GnRH/GnRHR
system to inhibit breast cancer cells migration. A key
point in this process might be the regulation of the cyto-
skeleton and extracellular matrix (ECM)-adhesion.
In the present study, we analyzed the molecular
mechanisms employed by the human GnRHR to regu-
late cell motility in the highly invasive breast cancer cell
line MDA-MB-231. We found that GnRHR activation by
the GnRHa, Buserelin, affected several cellular markers
of locomotion, including actin organization and
polymerization as well as active RhoA-GTP levels. The
cellular modifications observed correlated with high




The highly invasive breast cancer cell line, MDA-MB-
231 (MDA) [28] was obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA). The
MDA cells were cultured in Leibovitz’s medium supple-
mented with antibiotics and 10% fetal calf serum (FCS)
(Invitrogen, Carlsbad CA, USA) in a humidified chamber
at 37°C and 5% CO2. The breast cancer line MCF-7
(ATCC), was cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10%
FCS and antibiotics at 37°C and 5% CO2 in a humidified
atmosphere.
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Wild-type (WT) GnRHR (GeneBank access number
L07949; [29]) and mutant GnRHR lacking lysine at pos-
ition 191 (at the extracellular loop 2) (GnRHR-DesK191)
cDNAs, cloned in the expression vector pcDNA3.1
(Invitrogen) at Kpn1 and Xba1 sites (New England Bio-
Labs, Ipswich MA, USA) were synthesized as described
previously [30]. As previously shown [31], the GnRHR-
DesK191 is expressed at higher levels compared to the
WT receptor. The coding cDNA region of the human
guanine activating protein domain (GAP; amino acid resi-
dues 1248 to 1431) of the Rho-activating protein, p190Rho
GAP-A (GeneBank access number AF159851; [32]) was
isolated from total MCF-7 cells RNA by RT-PCR, and
cloned into the pcDNA3.1 vector at the restriction site
Xho1 (New England BioLabs). The dominant negative
mutant of the GAP domain (GAP-Y1284D) [33], was
constructed employing the QuickChange site-directed mu-
tagenesis kit (Stratagene, La Jolla, CA, USA); the mutagenic
oligonucleotide primers (Invitrogen) were designed accord-
ing to the sequence of the GAP domain mentioned above.
The fidelity of all constructions was verified by dye termin-
ator cycle sequencing (Perkin Elmer, Foster City CA, USA).
Transient transfection of MDA-MB231 cells
Wild-type and modified cDNA constructions were transi-
ently expressed in MDA cells. Transfections (800 ng DNA/
well) were performed employing the FuGENE HD transfec-
tion reagent (Roche Applied Science, Sandhofer, Mannheim,
Germany) following the manufacturer’s protocol. Briefly,
MDA cells were trypsinized and ~250,000 cells/well were
plated in 12-well culture plates (Costar, Cambridge, MA,
USA). For co-transfections, cells were transfected with WT
GnRHR and GAP domain cDNAs (GAP cells) or WT
GnRHR and GAP-Y1284D domain (GAP-Y1284D cells)
cDNAs at a 1:1 ratio. Experiments were performed 24 hours
after transfection. Cells transfected with empty pcDNA3.1
vector were employed as negative controls.
Radioligand binding assays
Radioligand binding assays were performed as previously
described [34]. Briefly, 100,000 cells per well were plated
in 24-well plates (Costar) and transfected as described
above. Twenty-four hours after start the transfection,
cells were washed twice with Lebovitz medium and 0.1%
BSA (Sigma, St. Louis MO, USA), and kept in FCS-free
growth media for 18 hours. Thereafter, cells were
washed twice and incubated at room temperature for 90
minutes in the presence or absence of excess (10 μM)
unlabeled Buserelin (Sigma) plus [125I]-Buserelin (spe-
cific activity, 700 mCi/mg). After the incubation, the
medium was removed and the cells were washed twice
with ice-cold PBS. Cells were then solubilized in 0.2 M
NaOH/0.1% SDS and counted.Measurement of inositol phosphate (IP) production
Inositol phosphates (IP) production was measured in
cells cultured in inositol phosphate-free medium and
preloaded with 4 μCi/ml [3H]-myo-inositol (New England
Nuclear, Boston MA, USA) for 18 hours at 37°C, as previ-
ously described [31,35]. Transfected cells (50,000 cells/well)
were exposed to Buserelin (10-11 to 10-7 M) for 2 hours
and then washed twice with inositol-free medium supple-
mented with 5 mM LiCl. Quantification of IP was deter-
mined by Dowex anion exchange chromatography and
liquid scintillation spectroscopy.
Measurement of F-actin
The amount of actin polymerized (F-actin) in adherent
cells stimulated with Buserelin was determined by fluor-
ometry [36] in transfected cells (250,000 cells/well) stimu-
lated with 10-7M Buserelin for 24 hours. Cells were then
fixed with 3.7% formaldehyde (Sigma) in PBS for 10 min-
utes, and permeabilized with 0.1% Triton X-100 (Sigma) in
PBS for 1 minute. F-actin was stained by incubating with
0.165 mM rhodamine-conjugated phalloidin (Molecular
Probes, Eugene OR, USA) during 20 minutes in the dark
at room temperature. Rhodamine bound to F-actin was
removed with methanol and read in a Fluroskan Ascent
Microplate Fluorometer (Thermo Scientific, USA) at 554
nm for excitation and 573 nm for emission. To determine
the relative amount of rhodamine bound to F-actin per
cell, five randomized fields per well were counted after
methanol extraction [37]. The relative F-actin content was
expressed as the amount of rhodamine-phalloidin per cell
in Buserelin-stimulated samples divided by the amount of
rhodamine-phalloidin per cell in control samples [38].
The amount of F-actin in suspended, GnRHa-stimulated
cells was determined by flow cytometric analysis [36].
Briefly, transfected cells in suspension (50,000 cells/tube)
were incubated in the absence or presence of 10-7 M
Buserelin for 2 hours at 37°C. Cell suspensions were then
fixed with 3.5% formaldehyde and quenched in 0.1 M
glycine for 30 minutes. After permeabilizing with 0.2%
Triton X-100-1% BSA, cells were stained with 0.165
mM rhodamine-phalloidin for 30 minutes. The amount
of F-actin was measured in a FACSAria flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) at 554 nm
excitation and 573 nm emission. At least 1000 events per
sample were analyzed. Data analysis was performed using
the Summit software version 4.3 (Dako Colorado Inc,
USA); the results expressed as the mean of fluorescence
intensity (rhodamine-phalloidin in Buserelin-stimulated
samples/rhodamine-phalloidin in control samples).
Confocal microscopy of F-actin
Arrangement of F-actin in transfected cells was visua-
lized by confocal microscopy as described elsewhere
[36]. Cells cultured on Histogrip (Invitrogen)-coated
Aguilar-Rojas et al. BMC Cancer 2012, 12:550 Page 4 of 11
http://www.biomedcentral.com/1471-2407/12/550coverslips were incubated in serum-free medium with
Buserelin (10-7M) during 24 hours. F-actin was stained
as described above and mounted on slides cover with
ProLong solution (Invitrogen). Samples were then visua-
lized in a Leica TCS SP5 MP multiphoton microscope
(Leica Microsystems,Wetzlar, Germany).
Focal adhesion (FA) and F-actin arrangement in adher-
ent cells to Collagen I were also evaluated by confocal
microscopy. Collagen I (Sigma)-coated coverslips were
placed in 24-well plates and transfected. Twenty-four
hours after transfection, cells (80,000/well) were stimu-
lated with Buserelin and stained with rhodamine-
phalloidin as described above. Mouse anti-vinculin IgG
monoclonal antibody (at a 1:200 dilution in PBS) and
FITC-conjugated anti-mouse IgG antibody (Millipore,
Temecula CA, USA) were added in tandem to visualize
focal adhesion [39]. Samples were mounted and visua-
lized as described above.
Measurement of Rho activity
Cells were plated in Collagen I-precoated, 10 mm culture
dishes (at a density of 2.125 x 106 cells/dish), transfected
and exposed to 10-7M of Buserelin in Lebovitz’s medium
for 24 hours. Measurement of GnRHa-stimulated active
RhoA-GTP was performed by a pull-down assay employ-
ing the Rho-binding domain (RBD) of Rhotekin coupled
to glutathione-S-transferase-sepharose (GST) (GE Health-
care Bio-Science, Uppsala, Sweden) and subsequent im-
munoblotting. RhoA-GTP was eluted with Laemmli
buffer following the protocol described previously with
minor modifications [40]. Eluates were electrophoresed in
7.5% SDS-PAGE and transferred to polyvinylidene fluoride
membranes (Millipore), and blots were probed with
mouse anti-Rho monoclonal antibody (Millipore) at a
1:1000 dilution. RhoA-GTP and total RhoA (from no pull-
down control extracts) levels were measured by densitom-
etry. Results are expressed as the ratio of RBD/GST-bound
Rho (RhoA-GTP)/total RhoA levels.
Adhesion assays to Collagen I
Cell adhesion to Collagen I was determined by a colori-
metric assay [41]. Transfected cells (20,000/well) cul-
tured in Collagen I-coated 96-well plates were incubated
for 24 hours at 37°C in FCS-free medium in presence or
absence of Buserelin (10-7M). Adherent cells were fixed
and stained with 0.1% crystal violet (Sigma) in methanol.
The absorbance of sodium citrate (0.1 M)-extracted dye
was then measured at 595 nm.
Quantification of F-actin during cell adhesion and cell
invasion
The amount of F-actin present in transfected, Collagen
I-adherent cells incubated in the presence or absence of
Buserelin (10-7M) as well as that present during ofinvasiveness conditions (i.e. cells cultured in the pres-
ence of FCS (10%)) were measured by fluorometry fol-
lowing the protocol described above [42].
Invasion assays
Invasion assays were carried out in 6.5 mm, Collagen I
(10 mg/ml)-coated Transwell Chambers separated by a
semipermeable membrane with a 8-μm pore size
(Costar) [43]. Cells were transfected as described above,
detached from culture plates and resuspended in serum-
free Leibovitz’s medium containing 0.1% BSA. One hun-
dred thousand cells were added to the upper chamber
and then incubated in the presence or absence of 10-7M
of Buserelin. Cells were allowed to migrate to the lower
chamber (containing Leibovitz’s medium/10% FCS, with
or without GnRHa) during 24 h at 37°C in 5% CO2, and
migrated cells were collected, pelleted, resuspended in
PBS, and counted [44].
Statistical analysis
All experiments were performed in triplicate incuba-
tions. Data were analyzed by one-way analysis of vari-
ance (ANOVA) followed by the Tukey’s multiple
comparison test. A value of P<0.05 was considered sta-
tistically significant. Statistical tests were performed
using the GraphPad software (GraphPad Software Inc.,
v. 4.1, La Jolla, CA, USA).
Results
Expression and functionality of transfected GnRHRs in
MDA-MB-231 breast cancer cells
Specific binding sites for [125I]-Buserelin and IP produc-
tion in response to agonist exposure were detected
in WT GnRHR-transfected cells. Since plasma cell sur-
face expression of the transfected WT GnRHR was rela-
tively low in this tumor cell line, the over-expressed
mutant form, GnRHR-DesK191 was also employed to
explore the effect of increased cell surface membrane-
expressed receptor levels on several cell markers asso-
ciated with locomotion dynamics. Compared to the WT
GnRHR, specific [125I]-Buserelin binding and Buserelin-
stimulated IP production of cells transfected with the
GnRHR-DesK191 were considerably increased (to 139 ±
19% and 590 ± 134% of WT levels, for total binding and
IP production, respectively) (Figures 1A and B). Relative
[125I]-Buserelin binding affinities were similar for the en-
dogenous receptor (empty vector-transfected) (Ki, 1.03 ±
0.20 μM), and the WT (Ki, 0.50 ± 0.15 μM) and
DesK191 (Ki, 0.70 ± 0.20μM) transfected GnRHRs, as
disclosed by radioligand-binding assays. Nevertheless,
the IP response was considerably reduced (by ~80%) in
cells transfected with the empty vector, thus reflecting
the low levels of endogenously expressed GnRHR in
MDA-MB-231 breast cancer cells (Figures 1A and B).
Figure 1 [125I]-Buserelin binding and IP production in MDA
cells expressing the WT GnRHR and GnRHR-DesK191 mutant. A.
Specific [125I]-Buserelin binding to MDA cells transfected with the
empty vector (pcDNA3.1), the WT GnRHR and the GnRHR-DesK191
cDNA constructs. B. Inositol phosphate dose–response curves for
Buserelin in MDA cells transiently expressing the WT GnRHR and
GnRHR-DesK191 mutant. Maximal IP production in cells transfected
with the WT GnRHR cDNA was set as 100% and all other values are
expressed relative to this. Assays were performed in triplicate
incubations and the results shown are the means ± SEM from three
independent experiments. *p<0.001; ** p<0.01 vs pcDNA3.1.
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The effect of GnRHR in F-actin cytoskeleton remodeling
was assessed in adherent MDA cells exposed to a satur-
ating concentration of Buserelin (10-7M). F-actin was
stained with rhodamine-phalloidin and quantified for
fluorometry. A significant (p< 0.05) increase in the rela-
tive amount of F-actin in WT and DesK191 GnRHRs-
expressing cells was observed in response to Buserelin
(Figure 2A). Although the amount of F-actin was higher
in cells transfected with the GnRHR-DesK191 than in
those transfected with the WT receptor, the difference
did not reach statistical significance. Conversely, actin
polymerization promoted by Buserelin-stimulated GnRHR
and GnRHR-DesK191 was significantly decreased in non-
adherent (p<0.05; Figure 2B). Thus, GnRH promoted actin
polymerization only in adherent cells.
Actin cytoskeleton arrangement after GnRHR activation in
MDA cells
Although the images did not show any substantial
change in the morphology of cells expressing the WT
and DesK191 GnRHRs in response to a saturating con-
centration of Buserelin (Figures 2C 1 and 4), a remarkable
increase in stress fibers crossing the cell body wasobserved as a result of GnRHa exposure (Figures 2C 2–3
and 5–6).
Rho activity in MDA cell adhered to Collagen I
The increase of F-actin as stress fibers in cells exposed
to Buserelin, strongly suggested that the GnRH/GnRHR
system might be linked to activation of RhoA GTPase,
which is responsible of stress fiber formation and focal
adhesion assembly [8]. To determine the impact GnRHR
activation on RhoA response, the levels of GTP-loading
RhoA were analyzed in MDA cells adhered to Collagen I
and stimulated with Buserelin. Negligible levels of GTP-
RhoA were observed in cells transfected with the empty
pcDNA3.1 vector, even in the presence of saturating
concentrations of Buserelin (Figure 3A). In contrast,
GTP-RhoA levels were significantly (p<0.01) increased
in GnRHa-stimulated WT GnRHR- and GnRHR-
DesK191-transfected cells, indicating that RhoA was
activated by GnRH in MDA cells. In order to more
deeply explore the association between RhoA and
GnRHR activation in these cells, the GAP domain of
p190RhoGAP as well as the dominant negative form of
this domain (GAP-Y1284D) were co-transfected with the
GnRHR and the Rho-GTP levels were determined after
Buserelin stimulation. Under these conditions, GTP-RhoA
protein levels were either suppressed or unaffected in cells
transfected with the GAP domain or the GAP-Y1284D,
respectively (Figure 3A and B).
Attachment to Collagen I and quantification of F-actin in
MDA cells
Cell attachment to the ECM is a function linked to RhoA
and actin cytoskeleton dynamics [45]. Keeping this in
mind, the effects of GnRHR activation on Collagen I adhe-
sion and actin polymerization during this condition
were determined. A substantial increase in cell adhesion
following GnRHa stimulation was observed in WT
GnRHR-, GnRHR-DesK191-transfected, and GAP-Y1284D/
GnRHR-co-transfected cells. By contrast, Buserelin-
stimulated adhesion was completely abolished in GAP do-
main/GnRHR-co-transfected cells (Figure 3C). As expected,
the amount of F-actin in cell adhesion conditions was
increased (p<0.01) after Buserelin activation in GnRHR-,
GnRHR-DesK191- and GAP-Y1284D-transfected cells.
Interesting, although in cells transfected with the GAP do-
main the amount of F-actin was the highest, polymerized
actin was observed only in the periphery but not across the
cell body (see below).
Arrangement of focal adhesion and F-actin upon GnRHR
activation in MDA cells
Cell attachment takes place through formation of focal
adhesion complexes via RhoA activity [46]. These adhe-
sion complexes favor the interactions between ECM-
Figure 2 Effects of Buserelin on actin polmerization in MDA cells. A. Buserelin (10-7M)-stimulated relative F-actin levels (in arbitrary units) in
adherent MDA cells transfected with the empty vector, the WT GnRHR or the GnRHR-DesK191 cDNAs, as determined by fluorometry. Cells
expressing the WT and DesK191 GnRHRs exhibited a significant increase in polymerized actin in response to the GnRHa. In each group (cells
transfected with the empty vector, WT GnRHR or GnRHR-DesK191), basal F-actin (i.e. no treatment) was set to 1.0 and Buserelin-stimulated levels
were expressed relative to this (horizontal line). B. Relative F-actin levels measured by flow cytometry in suspended MDA cells transfected with
the empty vector, the WT GnRHR or the GnRHR-DesK191 cDNA constructs. A significant decrease in polymerized actin was observed in response
to the GnRHa. C. Representative images from confocal microscopy of Buserelin (10-7M)-stimulated MDA cells transfected with the empty vector,
the WT GnRHR or the GnRHR-DesK191 cDNAs. Compared with untreated cells (lower panel) an increase in stress fibers (arrows) was apparent in
WT GnRHR and GnRHR-DesK191 cells exposed to the GnRHa (upper panel). Bar: 20μm. The results shown in A and B are the means ± SEM from 3
independent experiments. ** p< 0.05; *** p<0.05.
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with a number of other cytoplasmic proteins, including
talin, vinculin, paxillin, and alpha-actinin [47]. Since for-
mation of focal adhesion reflects cell adhesion to the
ECM, identification of these structures by vinculin
immunostaining was conducted in transfected MDA
cells plated on Collagen I. In agonist-stimulated GnRHR,GnRHR-DesK191 and GAP-Y1284D-transfected cells,
accumulation of intense fluorescent dots revealed the
presence of FA as well as high amount of stress fibers
across the cell body (Figure 4A, compare arrows in
panels 2, 3 and 5 with arrows in panels 7, 8 and 10). On
the other hand, treatment of GAP domain-transfected
cells led to complete absence of fluorescent vinculin dots
Figure 3 Effects of Buserelin on RhoA GTP expression and cell adhesion to Collagen I in MDA cells. A. Representative autoradiogram from
Western blots showing the effects of Buserelin on RhoA expression in MDA cells transfected with the empty vector, the WT GnRHR and the
GnRH-DesK191 cDNAs (lanes 1 to 3) or co-transfected with the WT GnRHR and p190RhoGAP or GAP-Y1284D cDNAs (lanes 4 and 5, respectively).
B. Densitometric analysis of Rho GTP activity as determined by pull-down assays and Western blotting of extracts from cells transfected or co-
transfected with the different expression plasmids and exposed to 10-7M Buserelin or vehicle. C. Assessment of adhesion to Collagen I in cells
transfected or co-transfected with the different GnRHRs and GAP expression plasmids described in A and exposed to Buserelin or vehicle. D.
Relative F-actin levels in the cell adhesion experiments shown in C, as disclosed by fluorometry. The results shown in B, C, and D are the means ±
SEM from 3 independent experiments. *p<0.05; **P < 0.01; ***p< 0.001.
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absence of FA in these particular cells. As noted above,
high amounts of peripheral F-actin were detected in
GAP-domain-transfected cells (Figure 4A, compare
arrows in panels 4 and 9 with arrows in panels 1 and 6).
Effects of GnRHR activation on invasion to Collagen I and
measurement of F-actin in invasion conditions
Since RhoA plays a pivotal role in cell migration through
regulating cytoskeletal changes and matrix adhesion dy-
namics [46], invasion of MDA cells transfected with the
GnRHRs to Collagen I was evaluated. In Transwells
Chambers covered with Collagen I and stimulated with
Buserelin, GnRHR-, GnRHR-DesK191, and GAP-Y1284D-
transfected cells showed a substantial reduction in inva-
sion ability (Figure 4B). This inhibition was abrogated in
the absence of active GTP-RhoA (GAP-domain-trans-
fected cells) (Figure 4B). Measurement of polymerizedactin during invasion showed that in contrast to control,
empty vector-transfected cells, GnRHR and mainly
GnRHR-DesK191 and GAP-Y1284D-transfected cells
exhibited a marked increase in the amount of F-actin in
the presence of Buserelin (Figure 4C), a finding that corre-
lated with their ability to adhere to Collagen I under simi-
lar conditions (Figure 4B). Analogously with the adhesion
experiments (see above), the amount of F-actin detected
in invasion assays was the highest in GAP domain-
transfected cells (Figure 4C).
Discussion
Metastases at distant sites are the main cause of death in
patients with breast cancer [48]. The metastatic process
involves a series of events in which changes in cell mo-
tility represent the hallmark of invasion and the initial
step in metastasis [6]. Over the past years, it has been
clearly established that GnRH and its receptor are
Figure 4 Effects of Buserelin on focal adhesion assembly and Collagen I invasion in MDA cells. A. Focal adhesion and F-actin arrangement
as disclosed by confocal microscopy. MDA cells were transfected with the WT and DesK191 GnRHRs or co-transfected the WT GnRHR and GAP
variants cDNAs, and exposed to 10-7M of Buserelin (upper panel) or vehicle (lower panel). The cells were then fixed and F-actin and Vinculin were
stained as described in Materials and Methods. An increase in focal adhesion and stress fibers can be observed in cells overexpressing the
GnRHRs as well as in those overexpressing the WT GnRHR and GAP-Y1284D (arrows in panels 2, 3 and 5), whereas cells co-transfected with the
WT GnRHR and the GAP domain cDNAs exhibited decreased focal adhesion and marked accumulation of F-actin in the periphery (arrows in
panels 4 and 9). Similar results were found in two other experiments. Bar: 10μm. B. The effect of GnRHR activation by Buserelin on cell invasion
capacity as determined by invasion assays in Collagen-1-covered Transwell Chambers. C. F-actin levels in cell invasion. Transfected cells were
attached to Collagen and exposed to Buserelin (10-7M) or vehicle in 10% FCS-supplemented medium, and the amount of F-actin was determined
by fluorometry. The results shown in B and C are the means ± SEM from 3 independent experiments. *p<0.05; **p< 0.01; ***p< 0.001.
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tumors from the reproductive system, including the
breast [26,27]. It has also been shown that binding of
GnRH to breast malignant tumor cells results in growthmodulation [18] and inhibition of metastatic capacity
[20]. Although activation of some signaling pathways
and effectors proteins involved in GnRHR-regulated cell
motility have been reported [17,24], the molecular
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presses cell migration is still unclear.
In the present study we assessed the effect of GnRH
on the invasiveness capacity of human breast cancer
MDA-MB-231 cells, an aggressive, highly invasive, and
estrogen unresponsive cell line [49]. To this end, we
overexpressed the GnRHR in MDA cells and analyzed
the effects of its cognate ligand on the pathways leading
to actin cytoskeleton activation and cell adhesion. MDA
cells transfected with the GnRHR (WT and DesK191)
cDNAs, specifically bound [125I]-Buserelin and produced
higher levels of the second messenger IP in response to
the GnRH analog than untransfected cells, overcoming
the problem related to the low naturally expressed
GnRHR levels in breast cancer cell lines [50,51]. In fact,
the increased expression levels and IP response to
GnRHa detected in GnRHR-transfected MDA cells,
emulated those previously detected in breast cancer cells
exhibiting high GnRHR expression levels [52]. Here we
confirm that to detect relevant effects of GnRH on
breast cancer cells function, it is necessary to substan-
tially increase cell surface plasma membrane receptor
levels, which is an important issue given that the num-
ber of GnRHRs is highly variable in malignant breast
tumors tissue [51]. In this scenario, measurement of
GnRHR density in malignant breast tissue may be useful
as a surrogate marker to predict the tumor responsive-
ness to GnRHa administration.
We have shown that in MDA cells, GnRHRs were able
to promote IP production upon activation by agonist.
Although we did not detect measurable changes in
cAMP levels after exposure to GnRHa in this particular
cell line (not shown), previous studies have found that
the inhibitory effects of GnRHa on other reproductive
cancers (including prostate and endometrial cancer) is
mediated by the Gαi protein [53-55]. Our data are con-
sistent with previous studies in MCF-7 breast cancer
cells, in which the GnRH/GnRHR system was capable to
selectively promote IP production [52]. These data sup-
port the idea that in extrapituitary tissues, the GnRHR
may couple to different G proteins and activate distinct
signaling pathways depending on the cell context, the
particular GnRH analog employed to activate the recep-
tor, and also probably the receptor density [56,57].
Actin polymerization is involved in cell migration and
thus is important in determining the invasiveness ability
of cancer cells [56]. Our results showed that Buserelin
promoted actin polymerization as stress fibers in WT and
Desk191 GnRHR-transfected adherent MDA cells, thus
suggesting that activation of the GnRH/GnRHR system
may be involved in the migratory potential of these malig-
nant cells. Since Buserelin-stimulated MDA cells displayed
many stress fibers and high F-actin levels, we analyzed the
effects of GnRHa on RhoA, a small GTPase involved inactin polymerization and formation of stress fibers. In fact,
previous studies have shown the effect of GnRH on actin
cytoskeleton via other members of the Rho GTPases fam-
ily [22,23]. We found that in Collagen I-adherent MDA
cells, exposure to GnRHa increased RhoA-GTP levels and
paralleled the amount of stress fibers. The effects of
GnRH in RhoA-GTP were verified by co-transfection
assays employing the GAP domain of p190RhoGAP and
its dominant negative mutant, GAP-Y1284D [33].
p190RhoGAP is a specific GAP for RhoA and its effect
represents more than 60% of the overall GAP activity in
the cell [57,58]. The results showed that GTPase RhoA
levels were abolished or unaltered in the presence of the
GAP domain or GAP-Y1284D, respectively, thus indicat-
ing the specificity of the GnRH/GnRHR system on this
particular small G protein. Concurrently, these data indi-
cates that the effects of GnRH on actin polymerization
and stress fibers assembly are mediated through activation
of RhoA in Collagen I-attached MDA cells.
To demonstrate that GnRH-activated GTP RhoA
promotes cell adhesion and thus may represent one of
the mechanisms whereby this G protein inhibits cell
migration, cell adhesion assays as well as confocal
visualization of FA (substrate binding sites) were per-
formed. In fact, previous studies have shown that RhoA
activity supports efficient substrate adhesion, reduces cell
detachment rate, and attenuates cell locomotion [59-61].
Our results showed that exposure of Collagen-I-adherent
MDA cells to the GnRHa promoted cell adhesion to sub-
strate and increased the number of FA. Further, cell
invisiveness of these GnRHa-exposed cells was abolished
as disclosed by invasion assays in Collagen-I-covered
Transwell Chambers.
Actin polymerization leads to membrane protrusion
and extracellular cell-matrix adhesion, which are gener-
ally considered as markers of the migration capacity of
different cell types [62]. In this vein, it was interesting to
find that in MDA cells co-transfected with the GnRHR
and the GAP domain, stimulation with Buserelin did not
promote detectable increments in cell adhesion to sub-
strate - but paradoxically, it increased the levels of F-actin
at the periphery of the cells. The observation that GAP
domain-cotransfected cells additionally showed mem-
brane protrusions similar to lamellipodia, suggests that
continuous activation of other GTPases, such as Rac1,
was present in these cells. In fact, previous studies have
demonstrated the ability of GnRH to stimulate this par-
ticular GTPase [22].
Our findings in MDA cells exposed to GnRH has also
been observed in other cell lines, and apparently the
effects of this decapeptide on cell migration depend on
the cell context. For example, it has been shown that
GnRH-mediated attenuation in migration capacity of
DU145 cells (prostate cancer-derived) is associated with
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activation as well. By contrast, in TSU-Pr1 cells (also
derived from prostate cancer cells) GnRH favors cell mi-
gration through mechanisms mediated by the GTPasas
Rac1 and Cdc42, and by formation of filipodia and
lamellipodia [23]. Our results suggests that in MDA cells
transfected with the GAP domain, the absence of active
RhoA GTPase promoted loss of the FA and hence in
their ability to adhere to substrate as it was observed in
response to GnRHa. In this scenario, the loss of migra-
tory capacity of these cells might have resulted from the
relative decrease in RhoA GTPase levels, since it is well
known that cell invasion requires the concourse of sev-
eral small G proteins [62].
Conclusion
In the present study, we provide evidence demonstrat-
ing that in the highly invasive human breast cancer
MDA-MB-231 cell line, activation of the GnRHR pro-
motes RhoA activation, actin cytoskeleton remodeling and
a remarkable increase in cell adhesion to substrate. Con-
currently, these data may explain the ability of GnRH to
reduce the metastatic potential and invasiveness of malig-
nant breast tumor cells.
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